Kamada (NASDAQ:KMDA) Issues Earnings Results

Kamada (NASDAQ:KMDA) released its earnings results on Wednesday. The biotechnology company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.05, FiscalAI reports. Kamada had a net margin of 11.21% and a return on equity of 7.73%. The firm had revenue of $54.92 million for the quarter, compared to analysts’ expectations of $50.84 million.

Here are the key takeaways from Kamada’s conference call:

• Record first-half performance: Revenue rose 13% year over year to $100.2 million, adjusted EBITDA increased 14% to $25.7 million, and net income grew 18% to $13.4 million. Second-quarter revenue and EBITDA also reached company records, with a 26% EBITDA margin.
• Kamada reiterated its 2026 guidance of $200 million–$205 million in revenue and $50 million–$53 million in adjusted EBITDA, noting that first-half results are approximately 50% of the annual midpoint and that it remains comfortable with second-half expectations.
• The company signed a three-year, $50 million normal-source plasma supply agreement, with initial commercial sales expected in the fourth quarter of 2026. Houston and San Antonio facilities are expected to provide roughly $16 million–$20 million of annual capacity, while specialty plasma will support Kamada’s own products.
• Management reported continued demand growth for KEDRAB, VARIZIG, HepaGam B and other commercial products, alongside expansion of its biosimilar distribution business in Israel and the MENA region. Kamada expects its biosimilar portfolio to generate $15 million–$20 million in annual sales within several years.
• CFO Chaime Orlev will leave the company at the end of 2026 after nine years, and Kamada has begun searching for a successor, creating a near-term executive-transition risk.

Kamada Stock Performance

Kamada stock traded down $0.18 during midday trading on Wednesday, reaching $6.91. 313,355 shares of the stock were exchanged, compared to its average volume of 60,486. The firm has a market cap of $397.39 million, a PE ratio of 19.74, a PEG ratio of 0.65 and a beta of 0.86. The company’s fifty day moving average is $7.23 and its 200-day moving average is $7.98. Kamada has a 52 week low of $6.50 and a 52 week high of $9.35.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on KMDA shares. Weiss Ratings downgraded Kamada from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 25th. Benchmark reissued a “buy” rating on shares of Kamada in a research report on Tuesday, July 21st. William Blair set a $15.00 target price on Kamada in a research note on Tuesday, July 21st. Finally, Wall Street Zen cut Kamada from a “buy” rating to a “hold” rating in a research report on Saturday, May 23rd. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Kamada has an average rating of “Buy” and a consensus target price of $13.00.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Cubist Systematic Strategies LLC bought a new stake in Kamada during the 1st quarter valued at approximately $206,000. NewEdge Advisors LLC grew its stake in shares of Kamada by 119.9% in the first quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company’s stock worth $341,000 after acquiring an additional 28,165 shares during the period. Goldman Sachs Group Inc. bought a new position in shares of Kamada during the 1st quarter valued at $497,000. Jane Street Group LLC bought a new stake in shares of Kamada during the 1st quarter valued at about $582,000. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in Kamada during the second quarter valued at approximately $472,000. 20.38% of the stock is owned by hedge funds and other institutional investors.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.